Biotechnology and Bioengineering · 2006 · 54 citations · 27 references
PharmacyCardiologyPharmaceuticsDrug DeliveryInterventional CardiologyTargeted Drug DeliveryAntibody-drug ConjugatesCardiovascular PharmacologyLiposome-based DeliveryTargeting LigandsCardiac TargetingEndothelial Adhesion MoleculesLiposomal NanocarriersMyocardial Infarction ModelsMyocardial Infarction PharmacotherapyPost-myocardial Infarction PharmacotherapySelectin LigandsVascular Targeting
Immunoliposome (IL) targeting to areas of inflammation after an acute myocardial infarction (MI) could provide the means by which pro-angiogenic compounds can be selectively targeted to the infarcted region. The adhesion of model drug carriers and ILs coated with an antibody to P-selectin was quantified in a rat model of MI following left coronary artery ligation. Anti-P-selectin coated model drug carriers showed a 140% and 180% increase in adhesion in the border zone of the MI 1 and 4 h post-MI, respectively. Radiolabeled anti-P-selectin ILs injected immediately post-MI and allowed to circulate 24 h showed an 83% increase in targeting to infarcted myocardium when compared to adjacent non-infarcted myocardium. Radiolabeled anti-P-selectin ILs injected 4 h post-MI and allowed to circulate for 24 h showed a 92% increase in accumulation in infarcted myocardium when compared to adjacent non-infarcted myocardium. Targeting to upregulated adhesion molecules on the endothelium provides a promising strategy for selectively delivering compounds to the infarct region of the myocardium using our liposomal-based drug delivery vehicle.
27
Heart Disease and Stroke Statistics—2006 Update
Thomas Thom, Nancy Haase, Wayne D. Rosamond et al. · Circulation · 2006 · 3.5K citations · Full text
Timothy D. Henry, Brian H. Annex, George R. McKendall et al. · Circulation · 2003 · 1K citations
Medicine, Cardiology, Pharmacology +14
Stephen E. Epstein, Ran Kornowski, Shmuel Fuchs et al. · Circulation · 2001 · 233 citations